Logo

PharmaShots Weekly Snapshot (October 15 - 20, 2018)

Share this

PharmaShots Weekly Snapshot (October 15 - 20, 2018)

  1. Mylan Launches MPA Injectable Suspension for Prevention of Pregnancy in the US

  Published: 18 Oct, 2018 | Tags: Mylan, Launches, MPA Injectable Suspension, Prevention of  Pregnancy, the US  

  1. Janssen Pharmaceuticals (J&J) Receives Health Canada’s Approval for Invokana (canagliflozin) in MACE Reduction

  Published: 17 Oct, 2018 | Tags: Janssen Pharmaceuticals, (J&J), Receives, Health Canada’s, Approval, Invokana (canagliflozin), MACE Reduction  

  1. Eiger Pharmaceuticals Reports Results of Lambda in P-II LIMT (Lambda MonoTx) Study in Hepatitis Delta Virus (HDV) Infection

  Published: 18 Oct, 2018 | Tags: Eiger Pharmaceuticals, Reports, Results, Lambda, P-II, LIMT (Lambda Monotherapy) Study, Hepatitis Delta Virus (HDV) Infection, LIFT, LIMT  

  1. Allergan Announces Completion of UBR-MD-04 & 3110-105-002 Study for Treatment of Migrane

  Published: 17 Oct, 2018 | Tags: Allergan, Announces, Completion, UBR-MD-04 & 3110-105-002 Study, Treatment, Migrane, Ubrogepant  

  1. Axsome Therapeutics Receives FDA’s Orphan Drug Designation for AXS-12 (reboxetine) to Treat Narcolepsy

Published: 17 Oct, 2018 |Tags: Axsome Therapeutics, Receives, FDA, Orphan Drug Designation, AXS-12 (reboxetine), Treat,  Narcolepsy  

  1. Novartis to Acquire Endocyte for Expansion of its Investigational Radioligand Therapy (RLT) Platform

  Published: 18 Oct, 2018 |Tags: Novartis, Acquire, Endocyte, Expansion , Investigational Radioligand Therapy (RLT) Platform, Lu-PSMA-617, Ac-PSMA-617  

  1. AbbVie Announces FDA’s Acceptance of sNDA for PR for Imbruvica (ibrutinib) + Gazyva (Obinutuzumab)

  Published: 17 Oct, 2018 |Tags: AbbVie, FDA, Acceptance, sNDA, PR, Imbruvica (ibrutinib), (Obinutuzumab) Gazyva  

  1. Palette Life Sciences Signs a Worldwide Commercialization and Development Agreement with Nestle Skin Health

  Published: 15 Oct, 2018 |Tags: Palette Life Sciences, Signs, Worldwide, Commercialization, Development, Agreement , Nestle Skin Health, Deflux IV  ,Solesta, Barrigel    

  1. Samsung Biogen Launches Imraldi (adalimumab, biosimilar) in EU for 14 Autoimmune Conditions

  Published:17 Oct, 2018 |Tags: Samsung Biogen, Launches, Imraldi (adalimumab, biosimilar), EU, 14 Autoimmune Conditions, Benepalitm , Flixabitm  

  1. Voyager to Present Preclinical Data of VY-HTT01 & VY-SOD102 at ESGCT 2018

  Published: 17 Oct, 2018 |Tags: Voyager, Present, Preclinical Data, VY-HTT01, VY-SOD102, ESGCT    2018  

  1. Ferring Signs a Research Colllaboration with Evotec to Develop Novel Small Molecule Therapies

  Published:17 Oct, 2018 |Tags: Ferring, Signs , Research Colllaboration,  Evotec , Develop, Novel Small Molecule Therapies  

  1. Regeneron’s Dupixent (Dupilumab) Achieves 1EP & 2EP in two P-III trial for Inadequately-Controlled Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

  Published:16 Oct, 2018 |Tags: Regeneron,  Dupixent (Dupilumab) ,Achieves, 1EP & 2EP,two P-III, Inadequately-Controlled Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)  

  1. AstraZeneca’s Lynparza (olaparib) Receives Fourth FDA’s Orphan Drug Designation to Treat Pancreatic Cancer

  Published:16 Oct, 2018 |Tags: AstraZeneca,  Lynparza (olaparib), Receives , Fourth, FDA, Orphan Drug Designation, Treat, Pancreatic Cancer  

  1. Google Developed AI System for Easy Detection of Last Stage Breast Cancer with 99% Accuracy

  Published:12 Oct, 2018 |Tags: Google, Developed, AI System, Easy Detection, Last Stage Breast Cancer, 99% Accuracy, LYNA, Inception-v3  

  1. Novartis Reports Results of Five-year P-III MEASURE 1 and FUTURE 1 study for AS and PsA

  Published:16 Oct, 2018 |Tags: Novartis, Reports, Results ,Five-year, P-III ,MEASURE 1 and FUTURE 1 study , AS and PsA  

  1. Amgen Launches Amgevita (adalimumab, biosimilar) in EU to Treat Inflammatory Diseases post EMA Approval in Feb 2017

  Published: 16 Oct, 2018 |Tags: Amgen, Launches, Amgevita (adalimumab, biosimilar),  Post, EU Approval , Treat, Inflammatory Diseases  

  1. Sarepta Signs an Exclusive Global (Except EU) License Agreement with Lysogene for LYS-SAF302 to Treat MPS IIIA

  Published: 15 Oct, 2018 |Tags: Sarepta, Signs, Exclusive, Global (Except EU) , License Agreement, Lysogene, LYS-SAF302, Treat, MPS IIIA  

  1. Roche Reports Kadcyla (trastuzumab emtansine) vs Herceptin (trastuzumab) Achieve 1EP in P-III KATHERINE study

  Published: 15 Oct, 2018 |Tags: Roche, Reports, Kadcyla (trastuzumab emtansine) ,Herceptin (trastuzumab), Achieve ,1EP, P-III KATHERINE study  

  1. Themis Biosciences Signs an Exclusive License Agreement with Max-Planck-Innovation for Oncolytic Virotherapies

  Published: 11 Oct, 2018 |Tags: Themis Biosciences ,Signs,Exclusive, License Agreement,Max-Planck-Innovation for Oncolytic Virotherapies  

  1. Therapiva Private Acquires Dr. Reddy’s API manufacturing Unit Jeedimetla, Hyderabad

  Published: 15 Oct, 2018 |Tags: Therapiva Private, Acquires, Dr. Reddy’s ,API manufacturing Unit ,Jeedimetla, Hyderabad, M&A  

  1. Merck Terminates Development and Commercialization Deal with Samsung Bioepis for Lusduna Nexvue (insulin glargine)

  Published:12 Oct, 2018 |Tags: Merck, Terminates , Development ,Commercialization, Deal, Samsung Bioepis, Lusduna Nexvue (insulin glargine)  

  1. Roche Announces Global Launch of NGS AVENIO Tumor Tissue Analysis Kits

  Published: 15 Oct, 2018 |Tags: Roche, Reports, Kadcyla (trastuzumab emtansine) ,Herceptin


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions